Loading...
NPI 1356385793 · Honolulu, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Honolulu, Hawaii. This profile covers 10 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 3221 Waialae Ave |
| City | Honolulu |
| State | HI |
| ZIP | 96816 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 15, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $472K |
| Medicaid | $63.2K |
LONGS DRUG STORES CALIFORNIA LLC is operating as a community/retail pharmacy with a clear emphasis on immunizations and point-of-care COVID services based on its code mix. The Medicare top codes include 91322 (COVID-19 vaccine), 90694 (influenza vaccine), and multiple administration codes such as 90480 and G0008, while Medicaid top codes mirror this pattern with 91322, 90471, and several influenza products, indicating routine retail pharmacy vaccine delivery and test dispensing. The NPI was enumerated on 2006-06-15 (~20 years ago), confirming a long-standing presence in the market rather than a recent entrant.
Medicare revenue is the dominant payer stream for this location: total Medicare revenue is $472K versus total Medicaid revenue of $63.2K. Revenue concentration on Medicare is high — the precomputed top 3 Medicare codes account for 64.3% of the provider's Medicare revenue — signaling that a small set of vaccine/test services drive most Medicare receipts for this entity.
Specific Medicare drivers show a mix of vaccines and COVID test provision. 91322 accounts for $131.3K (918 claims, $143 avg paid/claim) and 90694 accounts for $60.6K (808 claims, $75 avg paid/claim), while K1034 (10K claims, $11 avg paid/claim) contributes $110.2K; together these high-volume vaccine and test items align with the 64.3% concentration and reflect operational focus on immunization and COVID testing services.
On Medicaid the revenue mix is similarly concentrated but smaller in scale: the precomputed top 3 Medicaid codes account for 52.7% of Medicaid revenue. Key Medicaid contributors include 91322 ($12.8K, 112 claims) and 90471 ($10.9K, 995 claims), indicating that vaccines and vaccine administration are also the primary Medicaid revenue drivers at this site.
Competitive standing varies by code and payer: several Medicare codes rank highly nationally (for example 91322 ranks #73 of 29357 providers nationally and is listed at the 100th percentile) which suggests the location is a top-tier national reporter for that service, though the supplied label for many Medicare codes characterizes volumes as 'typical, unremarkable' indicating it participates strongly for those codes without appearing anomalous in utilization patterns. In-state Medicaid ranks show pockets of stronger performance for specific codes: 0134A ranks #4 of 39 providers in-state and 90674 ranks #6 of 64 providers in-state, both described as "notably above typical state volume," signifying above-average local activity for those items.
K1034 is a notable operational signal: 10K Medicare claims produced $110.2K in revenue and the code ranks #317 of 30143 providers nationally (99th percentile) while being described as 'typical, unremarkable volume.' This combination of very high claim count for a test distribution code and solid national rank indicates the pharmacy acts as a major distributor of nonprescription self-administered COVID tests for Medicare beneficiaries relative to most peers.
The provider shows a classic retail pharmacy service-line profile where relatively low-dollar, high-frequency items (e.g., K1034 tests and routine vaccine administration codes like 90480/G0008) generate meaningful cumulative revenue alongside higher-paid vaccine products (e.g., 91322 and 90694). This mix implies operational throughput focused on walk-in immunization and test services rather than specialty or procedure-based care.
Statistical labels in the source data identify areas of typical behavior and a few above-typical concentrations: multiple top Medicare codes are tagged 'typical, unremarkable volume' even when ranks are high, while Medicaid items 0134A and 90674 are explicitly 'notably above typical state volume.' Analysts should interpret this as a broadly consistent retail pharmacy pattern with localized outperformance on a small set of Medicaid vaccine codes rather than widespread anomalous billing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 920 | $140 | $131.3K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 10,020 | $10 | $110.2K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 810 | $80 | $60.6K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 160 | $280 | $44.8K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 920 | $40 | $39.5K |
| G0008 | Administration of influenza virus vaccine | 1,140 | $30 | $35.2K |
| 0134A | N/A | 570 | $40 | $24.3K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 300 | $70 | $21.8K |
| G0009 | Administration of pneumococcal vaccine | 160 | $10 | $1.4K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 10 | $30 | $460 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 110 | $110 | $12.8K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 1,000 | $10 | $10.9K |
| 0064A | N/A | 250 | $40 | $9.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 440 | $20 | $7.5K |
| 0134A | N/A | 160 | $40 | $6.1K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 120 | $40 | $4.7K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 160 | $30 | $4.2K |
| 0012A | N/A | 80 | $40 | $2.8K |
| 0011A | N/A | 60 | $40 | $2.4K |
| 90661 | This code represents a vaccine product administered into the muscle to protect against the flu virus. This is a trivalent vaccine, meaning it protects against three different strains of influenza.… | 50 | $30 | $1.2K |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90472 | This code represents each injection of a vaccine after the first; list this code in addition to the code for the first injection. | 32 | 50 | 50 | $40 | $33.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 26 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 6 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 43 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 34 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 48 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 9 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 10 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 4 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 6 | 60 | 50 | $20 | $1.3K |
Showing 1–10 of 13
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.